MARK2P15

Across TCGA pan-cancer cohorts, MARK2P15 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated MARK2P15 data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher MARK2P15 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MARK2P15 expression acts as an unfavorable survival marker.

CHOL, THYM, and READ are the cancer types where MARK2P15 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	DFS	Tertile	All	0.045	0.486	.009	45	view →
THYM	DFS	Tertile	All	0.075	0.885	<.001	36	view →
READ	DFS	Tertile	All	0.293	0.823	<.001	36	view →
CESC	DFS	Tertile	III,IV	0.193	0.633	.020	36	view →
OV	DFS	Tertile	IV	0.220	0.493	.010	24	view →
HNSC	DFS	Tertile	IV	0.203	0.473	.027	18	view →
LIHC	OS	Tertile	II,III,IV	0.128	0.617	.037	18	view →
PCPG	DFS	Tertile	All	0.535	0.935	.048	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

MARK2P15–CHOL (DFS)

Open the CHOL breakdown →